{Reference Type}: Journal Article
{Title}: KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients.
{Author}: Schäfer G;Bednarova N;Heidenreich A;Klocker H;Heidegger I;
{Journal}: Transl Androl Urol
{Volume}: 10
{Issue}: 10
{Year}: Oct 2021
{Factor}: 2.479
{DOI}: 10.21037/tau-20-1084
{Abstract}: <B>UNASSIGNED: </B>The administration of docetaxel chemotherapy is one therapeutic option to delay disease progression and increase overall survival in metastatic castration resistant prostate cancer (mCRPC). However, about 15% of patients are primary resistant to chemotherapy and hence would benefit from an alternative mCRPC treatment. Despite intensive research, there are no robust clinical validated biomarkers to predict mCRPC therapy response. Thus, the aim of the study was to determine KDM5D expression in archival radical prostatectomy specimens of patients medicated with docetaxel at time of mCRPC development in order to correlate KMD5D expression with treatment response.<BR><B>UNASSIGNED: </B>We used in situ hybridization (ISH) (RNA scope 2.5 HD) to determine KDM5D expression in tissue samples of 28 prostate cancer patients. KDM5D status was correlated to chemotherapy response (PSA and radiographic response).<BR><B>UNASSIGNED: </B>Data revealed that KDM5D is significantly overexpressed in tumor cells (P<0.0001) but also in benign cells (P<0.02) of those patients who responded to chemotherapy compared to non-responders.<BR><B>UNASSIGNED: </B>To summarize, KDM5D is a promising novel biomarker predicting response to docetaxel chemotherapy already at the time of localized disease and thus potentially avoiding metastatic biopsies in the mCRPC stage of disease.